XOMAP
XOMA Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
Market Cap: 287 Million
Primary Exchange: NASDAQ
Website: https://www.xoma.com/
Shares Outstanding: 880 Thousand
Float: 0
Dividend: 2.0209561860603844 (0.08%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 218 trading days
From: 2023-02-27 To: 2023-12-15
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2023-01-03 | 2023-01-17 | 2023-01-04 | 2022-12-22 | 0.53906 | Cash | |||
| 2023-04-03 | 2023-04-17 | 2023-04-04 | 2023-03-21 | 0.53906 | Cash | |||
| 2023-06-30 | 2023-07-17 | 2023-07-03 | 2023-06-20 | 0.53906 | Cash | |||
| 2023-10-04 | 2023-10-16 | 2023-10-05 | 2023-09-25 | 0.53906 | Cash | |||
| 2024-01-02 | 2024-01-16 | 2024-01-03 | 2023-12-20 | 0.53906 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|